Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

(2022) Naim Alkhouri et al.   JOURNAL OF HEPATOLOGY

Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials

(2022) Lei Sun et al.   Clinics and Research in Hepatology and Gastroenterology

Primary data analyses of MAESTRO-NAFLD-1 a 52 week double-blind placebo-controlled phase 3 clinical trial of resmetirom in patients with NAFLD

(2022) Stephen Harrison et al.   JOURNAL OF HEPATOLOGY

Mechanisms and disease consequences of nonalcoholic fatty liver disease

(2021) Rohit Loomba et al.   CELL

Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double‐Blind Phase 2 Trial

(2021) Samer Gawrieh et al.   HEPATOLOGY

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease

(2021) Atsushi Nakajima et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

(2021) Stephen A. Harrison et al.   NATURE MEDICINE

Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial

(2021) V. Ratziu et al.   NATURE MEDICINE

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

(2021) Sven M. Francque et al.   NEW ENGLAND JOURNAL OF MEDICINE

EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study

(2021) Vlad Ratziu et al.   JOURNAL OF HEPATOLOGY

Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial

(2020) Keyur Patel et al.   HEPATOLOGY

Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials

(2020) Stephen A. Harrison et al.   JOURNAL OF HEPATOLOGY

Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges

(2020) Jean-François Dufour et al.   GUT

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

(2020) Mohammed Eslam et al.   JOURNAL OF HEPATOLOGY

VK2809, a novel liver-directed thyroid receptor agonist, produces durable reductions in liver fat in patients with non-alcoholic fatty liver disease: results of 4-week follow-up assessment from a 12-week phase 2 randomized, placebo-controlled trial

(2020) Brian Lian et al.   JOURNAL OF HEPATOLOGY

Is vitamin D receptor a druggable target for non-alcoholic steatohepatitis?

(2020) Ying Cao et al.   WORLD JOURNAL OF GASTROENTEROLOGY

FGF19 and FGF21: In NASH we trust

(2020) Saswata Talukdar et al.   Molecular Metabolism

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

(2020) Philip N. Newsome et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis

(2020) Mohammad Shadab Siddiqui et al.   Clinical Gastroenterology and Hepatology

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study

(2019) Stephen A. Harrison et al.   JOURNAL OF HEPATOLOGY

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2019) Stephen A Harrison et al.   LANCET

A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial

(2019) Marcos Pedrosa et al.   Contemporary Clinical Trials

Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension

(2019) Naga Chalasani et al.   GASTROENTEROLOGY

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease

(2018) Noura S. Abul-Husn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of Insulin Action and Insulin Resistance

(2018) Max C. Petersen et al.   PHYSIOLOGICAL REVIEWS

Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease

(2017) Oscar Chávez-Talavera et al.   GASTROENTEROLOGY

What have human experimental overfeeding studies taught us about adipose tissue expansion and susceptibility to obesity and metabolic complications?

(2017) D J Cuthbertson et al.   INTERNATIONAL JOURNAL OF OBESITY

Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis

(2017) Cyrielle Caussy et al.   JOURNAL OF CLINICAL INVESTIGATION

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus

(2016) Kenneth Cusi et al.   ANNALS OF INTERNAL MEDICINE

Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease

(2016) Quentin M. Anstee et al.   GASTROENTEROLOGY

The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent

(2016) Rosellina Margherita Mancina et al.   GASTROENTEROLOGY

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

Molecular Pathogenesis of NASH

(2016) Alessandra Caligiuri et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016)   JOURNAL OF HEPATOLOGY

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies

(2015) Siddharth Singh et al.   Clinical Gastroenterology and Hepatology

Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States

(2015) Robert J. Wong et al.   GASTROENTEROLOGY

Liver X receptor regulates hepatic nuclear O-GlcNAc signaling and carbohydrate responsive element-binding protein activity

(2015) Christian Bindesbøll et al.   JOURNAL OF LIPID RESEARCH

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

(2015) Erin K. Spengler et al.   MAYO CLINIC PROCEEDINGS

Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis

(2014) Yang Jiao et al.   ACTA PHARMACOLOGICA SINICA

Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease

(2014) Julia Kozlitina et al.   NATURE GENETICS

Reciprocal Regulation of Hepatic and Adipose Lipogenesis by Liver X Receptors in Obesity and Insulin Resistance

(2013) Simon W. Beaven et al.   Cell Metabolism

A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)

(2013) Rajendrakumar H. Jani et al.   Diabetes Technology & Therapeutics

Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)

(2013) Maria Stepanova et al.   DIGESTIVE DISEASES AND SCIENCES

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY

PNPLA3 I148M polymorphism and progressive liver disease

(2013) Paola Dongiovanni   WORLD JOURNAL OF GASTROENTEROLOGY

Skeletal Muscle Insulin Resistance Promotes Increased Hepatic De Novo Lipogenesis, Hyperlipidemia, and Hepatic Steatosis in the Elderly

(2012) C. Flannery et al.   DIABETES

Solute carrier family 2 member 1is involved in the development of nonalcoholic fatty liver disease

(2012) Mercedes Vazquez-Chantada et al.   HEPATOLOGY

When Galectins Recognize Glycans: From Biochemistry to Physiology and Back Again

(2011) Santiago Di Lella et al.   BIOCHEMISTRY

National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants

(2011) Mariel M Finucane et al.   LANCET

Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease

(2010) P. Dongiovanni et al.   GUT

Apolipoprotein C3 Gene Variants in Nonalcoholic Fatty Liver Disease

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inflammasome-mediated regulation of hepatic stellate cells

(2009) Azuma Watanabe et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

The Role of Peroxisome Proliferator-Activated Receptor γ Coactivator-1 β in the Pathogenesis of Fructose-Induced Insulin Resistance

(2009) Yoshio Nagai et al.   Cell Metabolism

The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver

(2009) Nicola L. Beer et al.   HUMAN MOLECULAR GENETICS

Selective versus Total Insulin Resistance: A Pathogenic Paradox

(2008) Michael S. Brown et al.   Cell Metabolism